VXRT - Vaxart Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 SPY (6.72%) ETHUSD (%) WMT (5.52%) ENDP (0.95%) CAPR (10%) BTCUSD (%) AVGO (7.77%) ATHX (-2.09%) ADT (5.04%) AAPL (8.73%) SPCE (0%) SNAP (9.95%) SHOP (0%) RWT (0%) ROSE (0%) RNG (0%) RH (0%) RDHL (0%) QQQ (0%) PINS (0%) OPK (0%) ONCS (0%) OKTA (0%) NVDA (0%) LPSN (0%)

VXRT - Vaxart

$1.72 0.02[1.18%]

15 mins delayed data

People also watch :

+Watchlist

2 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$1.72	Open
Volume	13.9K	Market Cap	10.81M
Yield		Last Dividend

Day

52 Week

10 Biotech Winners And Losers In Q1	04/01/20
The quarter was brutal to say the least for most asset classes amid the coronavirus (COVID-19) pandemic. The S&P 500 Index was down about 20% for the ...

Vaxart, Emergent Biosolutions Partner On...	03/18/20
Vaxart Inc (NASDAQ: VXRT ) shares were advancing Wednesday following an update from the company on its COVID-19 vaccine program. Vaxart said it has en...

A Vaccine for Coronavirus? These 3 Healt...	02/12/20
Fear and uncertainty have gripped the global population as the number of confirmed coronavirus cases grows daily. What started in Wuhan, the capital o...

Vaxart (VXRT) to Make Vaccines to Check ...	02/03/20
Vaxart (VXRT) begins a program to develop a vaccine candidate to counter the new coronavirus infection. Shares jump.

Vaxart's stock rockets on heavy volume a...	01/31/20
Shares of Vaxart Inc. rocketed 54% on heavy volume in afternoon trading, putting them on track for the first close above the $1 mark in nearly 10 mont...

Zacks: Vaxart Inc (NASDAQ:VXRT) Given Co...	11/12/19
Vaxart Inc (NASDAQ:VXRT) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the sto...

Armistice Capital Master Fund Purchases ...	11/12/19
Vaxart Inc (NASDAQ:VXRT) major shareholder Armistice Capital Master Fund acquired 200,000 shares of the company???s stock in a transaction that occurr...

Vaxart : Hosting Key Opinion Leader Meet...	11/06/19
PDF Version Norovirus represents a $3+billion U.S. market opportunity SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 -- Vaxart, Inc. , a clinical-stage bi...

The Daily Biotech Pulse: Enanta Aces Mid...	09/26/19
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs S...

The Daily Biotech Pulse: Glaukos To Buy ...	08/08/19
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 7) A...

Dosing underway in early-stage study of ...	04/16/19
No summary available.

Vaxart down 22% on equity offering	04/08/19
No summary available.

Microcaps dominate midday movers	04/08/19
No summary available.

Vaxart +8% on completing dosing in norov...	03/27/19
No summary available.

Vaxart closes $3M capital raise	03/20/19
No summary available.

Cytokinetics and Fibrocell Science among...	03/20/19
No summary available.

FDX and TME among premarket losers	03/20/19
No summary available.

Sorrento Therapeutics and Altimmune amon...	03/19/19
No summary available.

SDRL, SBGL and CRBP among premarket gain...	03/19/19
No summary available.

Vaxart +16% on initiating norovirus vacc...	03/19/19
No summary available.

Vaxart files for 6M-share stock offering...	02/20/19
No summary available.

ANALYST RATINGS

0 analyst ratings (Last 6 months)

0.00 %

Strong Buy + Buy

Price Target (PT)

EARNINGS

Date	04/12/2019 (AMC)	Est. (EPS/Rev.)	$1.37
Actual (EPS/Rev.)	$2.5B	EPS (TTM)	$???

TRADERS TRACKING $VXRT

Service Name	Trader	% Success
Tech Trades	Ravi	84.00 %	Follow
Arbitrage Trade Analytics	Royce Wells	71.00 %	Subscribe

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Follow Us

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.